Weiss Ratings reissued their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF – Free Report) in a research note published on Wednesday morning,Weiss Ratings reports.
180 Life Sciences Price Performance
NASDAQ ATNF opened at $0.99 on Wednesday. The firm has a 50-day moving average price of $0.99 and a two-hundred day moving average price of $1.35. 180 Life Sciences has a 12-month low of $0.66 and a 12-month high of $17.75.
180 Life Sciences (NASDAQ:ATNF – Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.67) earnings per share for the quarter.
Hedge Funds Weigh In On 180 Life Sciences
About 180 Life Sciences
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.
Featured Stories
- Five stocks we like better than 180 Life Sciences
- Technology Stocks Explained: Here’s What to Know About Tech
- Is Consumer Discretionary a Dead End? These 3 Stocks Say No
- What is MarketRank™? How to Use it
- Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile
- What is the Hang Seng index?
- Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive?
Receive News & Ratings for 180 Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 180 Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.